[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abnormal-uterine-bleeding-aub\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abnormal-uterine-bleeding-aub":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100053825","office-hysteroscopy-in-postmenopausal-women-a-randomized-trial-of-cervical-preparation-strategies-100053825",false,"NCT07697781","Office Hysteroscopy in Postmenopausal Women: A Randomized Trial of Cervical Preparation Strategies","A Four-Arm Prospective Randomized Controlled Trial Comparing Oral Misoprostol, Two Vaginal Estrogen Regimens, and No Cervical Preparation Before Office Hysteroscopy in Postmenopausal Women","Inclusion Criteria:\n\n* Women with postmenopausal status.\n* Scheduled for office hysteroscopy for the evaluation of suspected intrauterine pathology.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Known or suspected hormone-dependent malignancy (e.g., breast or endometrial cancer).\n* Active genital tract infection.\n* Contraindication or known hypersensitivity to misoprostol or vaginal estrogen.\n* Refusal to undergo office hysteroscopy without anesthesia.\n* Active uterine bleeding preventing adequate hysteroscopic visualization on the day of the procedure.","FEMALE",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this randomized controlled trial is to evaluate the effectiveness of different cervical preparation strategies before office hysteroscopy in postmenopausal women undergoing evaluation for intrauterine pathology.\n\nThe main questions to answer are:\n\nDoes cervical preparation improve the success rate of complete office hysteroscopy in postmenopausal women? Which cervical preparation strategy provides better patient tolerance, as assessed by pain intensity during the procedure?\n\nResearchers will compare four cervical preparation protocols (14-day vaginal estrogen, 7-day vaginal estrogen, oral misoprostol, and no cervical preparation) to determine their effects on procedural success, pain, procedure duration, and perioperative complications.\n\nParticipants will be randomly assigned to one of the four cervical preparation protocols. They will undergo office hysteroscopy using a vaginoscopic (\"no touch\") approach without anesthesia. Then, they will have pain assessed using a visual analog scale (VAS) during the procedure. Finally, these informations will be collected: procedural success, procedure duration, bleeding, and perioperative complications.",[25,26,27,28,29],"Postmenopausal Women","Intrauterine Diseases","Endometrial Pathology","Postmenopausal Bleeding","Abnormal Uterine Bleeding (AUB)",[31,32,33,34,35,36,37,38,39],"Postmenopausal women","Postmenopausal bleeding","Office hysteroscopy","Cervical preparation","Vaginal estrogen","Oral misoprostol","Visual Analog Scale","Vaginoscopy","No touch approach","RECRUITING","2026-07-09",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":44},"2026-01-02",{"date":48,"type":19},"2026-08-20",{"name":50,"class":51},"Faculty of Medicine of Tunis","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":65,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":52},"100053696","menstrual-cycle-symptoms-and-female-health-100053696","NCT07699224","Menstrual Cycle Symptoms and Female Health","Prevalence of Subclinical Ovulatory Disturbances and Symptoms During the Menstrual Cycle and Their Relationship With Physical and Mental Health in Spanish Women of Reproductive Age (Prevalencia de Alteraciones Ovulatorias subclínicas y síntomas Durante el CICLO Menstrual y su relación Con la Salud física y Mental en Mujeres españolas en Edad Reproductiva).","CICLOS","Inclusion Criteria:\n\n* Females\n* Between 18 and 45 years\n* Naturally menstruating.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Hormonal contraceptive methods during the 6 months before the study.\n* hysterectomy or ooforectomy.\n* Smoking.","18 Years","45 Years",{"count":64,"type":19},400,"5 Months","OBSERVATIONAL","The complexity inherent to the hormonal fluctuations associated with the female menstrual cycle (MC) has contributed, from a methodological perspective in research, to the neglect of women's physiological characteristics and to the silencing and normalization of symptoms linked to different life stages and hormonal environments. The scarce and outdated available data suggest high percentages of women experiencing perimenstrual symptoms, such as premenstrual syndrome or menstrual pain, as well as intermenstrual discomfort. These symptoms not only significantly impair daily activities but, due to their normalization, often lead to the underdiagnosis of other gynecological conditions.\n\nSubclinical ovulatory disturbances-characterized by the suppression of ovarian hormones as an adaptive defense mechanism against various environmental stressors-are also frequently underdiagnosed. These disturbances typically do not affect MC length, making them difficult to detect, and although the process is reversible, it may initiate irreversible consequences for certain tissues, such as bone mass loss. However, neither women nor their educational, occupational, or healthcare environments appear to have the resources and\u002For knowledge required to adequately address these issues.\n\nAll of this may compromise women's rights to adequate sexual and reproductive health and to a dignified quality of life, as recognized under the second line of Axis 4, \"Effective Rights for All Women,\" of the Strategic Plan for Effective Equality between Women and Men 2022-2025. Therefore, the aims of this multicenter project-carried out by a multidisciplinary research team from seven Spanish universities and three international institutions-are to describe the prevalence of symptoms and alterations related to the MC in women of reproductive age and to identify their associations with physical and mental health.\n\nTo accomplish this, an observational study will be conducted in a large sample of women of reproductive age, including multiple symptom and perceived-health questionnaires and ovulation monitoring. In addition, in a subsample of participants, bone mineral density will be assessed, blood levels of sex hormones will be monitored, and an innovative analysis of health biomarkers (glycemic and lipid profile, and inflammation) from menstrual blood will be included. This will be complemented by a qualitative study of experiences related to MC-associated symptoms and alterations, using in-depth interviews and thematic content analysis.\n\nThe findings of this project are expected to support various dissemination and educational actions, justify the design of more inclusive educational and healthcare policies, and enhance the understanding of women's needs, ultimately contributing to improved symptom management and quality of life.",[69,70,71,29,72,73],"Menstrual Cycle","Menstrual Distress (Dysmenorrhea)","Premenstrual Syndrome","Ovulation Disorder","Perceived Health Status","2026-07-08",{"date":43,"type":44},{"date":77,"type":44},"2026-01-21",{"date":79,"type":19},"2026-12",{"name":81,"class":51},"Universidad Rey Juan Carlos",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":52},"100634822","endometrial-cancer-vaginal-fluid-specimen-collection-study-100634822","NCT07544680","Endometrial Cancer Vaginal Fluid Specimen Collection Study","Endometrial Cancer Vaginal Fluid Specimen Collection Study: \"ENVISION\"","ENVISION","Inclusion Criteria\n\nCohort 1 Participants:\n\n* Age ≥ 45 years, OR age ≥ 18 years with at least one risk factor\n* Diagnosed with abnormal uterine bleeding (AUB)\n* Planning standard-of-care endometrial tissue sampling to assess for endometrial cancer (EC) or atypical endometrial hyperplasia\u002Fendometrial intraepithelial neoplasia (AEH\u002FEIN)\n\nCohort 2 Participants:\n\n* Age ≥ 18 years\n* Newly diagnosed, biopsy-confirmed EC or AEH\u002FEIN\n* Planning initial management for their endometrial pathology\n\nExclusion Criteria\n\n* Prior partial or complete hysterectomy\n* Current pregnancy\n* Prior pelvic or vaginal radiotherapy\n* Chemotherapy within past 5 years (except tamoxifen)\n* Any condition judged by the Investigator to preclude participation\n\nAdditional for Cohort 1:\n\n* Cancer diagnosis within past 5 years (except non-gynecologic skin cancer)\n* Current biopsy-proven cervical, vaginal, or vulvar cancer, or lower genital tract dysplasia\n* Current biopsy-proven endometrial cancer, hyperplasia, or benign polyp\n* Benign endometrial biopsy within last month\n\nAdditional for Cohort 2:\n\n* Cancer diagnosis other than EC within past 5 years (except non-gynecologic skin cancer)\n* Prior cervical cancer or biopsy-proven cervical dysplasia\n* Surgery for recurrent EC\n* Preoperative neoadjuvant chemotherapy or radiotherapy for current EC\n* Prior treatment or surgery to remove target pathology during current episode",{"count":91,"type":19},4200,"This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.",[29,94,95,96,97],"Endometrial Cancer","Atypical Endometrial Hyperplasia","Endometrial Hyperplasia With Atypia","Endometrial Intraepithelial Neoplasia",[29,99,100,101,102,103,104,105,106,107],"Endometrial Cancer (EC)","Atypical Endometrial Hyperplasia (AEH)","Endometrial Hyperplasia with Atypia","Endometrial Intraepithelial Neoplasia (EIN)","Precancerous Conditions","Post-Menopausal Bleeding","Specimen Collection","Sample Collection","in vitro diagnostic (IVD) devices","2026-04-15",{"date":110,"type":44},"2026-04-22",{"date":112,"type":44},"2026-03-10",{"date":114,"type":19},"2028-04-24",{"name":116,"class":117},"Exact Sciences Corporation","INDUSTRY"]